<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Chem. Biol</journal-id>
<journal-title>Frontiers in Chemical Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Chem. Biol</abbrev-journal-title>
<issn pub-type="epub">2813-530X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1377357</article-id>
<article-id pub-id-type="doi">10.3389/fchbi.2024.1377357</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Chemical Biology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Impact of different spacers on the conjugation between Anderson-Evans polyoxometalates and peptides</article-title>
<alt-title alt-title-type="left-running-head">Yu et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fchbi.2024.1377357">10.3389/fchbi.2024.1377357</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Haihong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Honisch</surname>
<given-names>Claudia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Frigo</surname>
<given-names>Mattia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2641948/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Balice</surname>
<given-names>Nicola</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tagliavini</surname>
<given-names>Valeria</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Xue</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stramiglio</surname>
<given-names>Elisabetta</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2676511/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Campofelice</surname>
<given-names>Ambra</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2641988/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Serrat&#xec;</surname>
<given-names>Simona</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1381023/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Azzariti</surname>
<given-names>Amalia</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2228435/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Porcelli</surname>
<given-names>Letizia</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1933150/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zanetti Polzi</surname>
<given-names>Laura</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Corni</surname>
<given-names>Stefano</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ruzza</surname>
<given-names>Paolo</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1643029/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Carraro</surname>
<given-names>Mauro</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/556223/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Chemical Science</institution>, <institution>University of Padova</institution>, <addr-line>Padova</addr-line>, <country>Italy</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Institute of Biomolecular Chemistry of CNR</institution>, <institution>Padova Unit</institution>, <addr-line>Padova</addr-line>, <country>Italy</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Key Laboratory for Modern Drug Delivery &#x26; High-Efficiency</institution>, <institution>School of Pharmaceutical Sciences and Technology</institution>, <institution>Tianjin University</institution>, <addr-line>Tianjin</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Laboratory of Experimental Pharmacology</institution>, <institution>IRCCS Istituto Tumori Giovanni Paolo II</institution>, <addr-line>Bari</addr-line>, <country>Italy</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>CNR Institute of Nanoscience (CNR-NANO)</institution>, <addr-line>Modena</addr-line>, <country>Italy</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Institute on Membrane Technology (ITM-CNR)</institution>, <institution>UOS of Padova</institution>, <addr-line>Padova</addr-line>, <country>Italy</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/548951/overview">Luk&#xe1;&#x161; Krivosudsk&#xfd;</ext-link>, Comenius University, Slovakia</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/513609/overview">Nadiia I. Gumerova</ext-link>, University of Vienna, Austria</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2039646/overview">Rami Oweini</ext-link>, University of La Verne, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Paolo Ruzza, <email>paolo.ruzza@unipd.it</email>; Mauro Carraro, <email>mauro.carraro@unipd.it</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>25</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>3</volume>
<elocation-id>1377357</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>01</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>03</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Yu, Honisch, Frigo, Balice, Tagliavini, Zhao, Stramiglio, Campofelice, Serrat&#xec;, Azzariti, Porcelli, Zanetti Polzi, Corni, Ruzza and Carraro.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Yu, Honisch, Frigo, Balice, Tagliavini, Zhao, Stramiglio, Campofelice, Serrat&#xec;, Azzariti, Porcelli, Zanetti Polzi, Corni, Ruzza and Carraro</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The Anderson-Evans polyoxometalates (POM) display a promising anticancer activity. The conjugation with the GRP-receptor antagonist peptide Demobesin (fQWAVGHL-NHEt) was exploited to impart cell targeting capabilities and improve the selectivity of such polyanions. However, the POM interacts with the grafted peptides, inducing chains folding and self-assembly of the resulting hybrids, thus decreasing their recognition ability. Within this context, a tailored spacer, including two domains, i.e., a hydrophilic one (1,13-diamino-4,7,10-trioxatridecan-succinamic acid, Ttds) and a tetra-anionic one (Glu-Glu-Glu-Glu-&#x3b2;Ala, EEEE-&#x3b2;A) was previously utilized to mitigate such interaction. In this work, hybrid POMs containing only Ttds or EEEE-&#x3b2;A were prepared and the contribution of the two spacers was separately studied by using 2D NMR, fluorimetry and circular dichroism (CD). Transmission electron microscopy (TEM) was also used to observe the impact of the different spacers on self-assembly. Owing to the relevant effects observed for EEEE-&#x3b2;A, MD calculations were finally performed to elucidate its behavior when incorporated in the hybrid POM. Our results show that, despite the stronger impact of EEEE-&#x03B2;A spacer, only when both spacer are present together it is possible to observe a significant effect on the retention of peptide's secondary structure and recognition capability.</p>
</abstract>
<kwd-group>
<kwd>peptides</kwd>
<kwd>polyoxometalates</kwd>
<kwd>targeting</kwd>
<kwd>2D NMR</kwd>
<kwd>MD calculations</kwd>
</kwd-group>
<contract-num rid="cn001">PRIN2022CAS9ZT</contract-num>
<contract-num rid="cn002">P-DiSC&#x23;11NExuS_BIRD2019-UNIPD</contract-num>
<contract-sponsor id="cn001">Ministero dell&#x27;Universit&#xe0; e della Ricerca<named-content content-type="fundref-id">10.13039/501100021856</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Dipartimento di Scienze Chimiche, Universit&#xe0; degli Studi di Padova<named-content content-type="fundref-id">10.13039/501100024015</named-content>
</contract-sponsor>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Bioinorganic Chemistry</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Polyoxometalates (POMs), a class of polynuclear oxo-bridged transition metal complexes (<xref ref-type="bibr" rid="B9">Blazevic and Rompel, 2016</xref>), have received extensive attention due to their rich topology and tunable chemical and physical properties. In addition to their application in multidisciplinary fields (<xref ref-type="bibr" rid="B35">Omwoma et al., 2015</xref>), such as material science (<xref ref-type="bibr" rid="B54">Yu et al., 2023</xref>) and catalysis (<xref ref-type="bibr" rid="B51">Wang and Yang, 2015</xref>), their biomedical activity (<xref ref-type="bibr" rid="B15">&#x10c;olovi&#x107; et al., 2020</xref>), as antitumor (<xref ref-type="bibr" rid="B8">Bijelic et al., 2019</xref>), antiviral (<xref ref-type="bibr" rid="B16">Dan et al., 2020</xref>), and antibacterial (<xref ref-type="bibr" rid="B7">Bijelic et al., 2018</xref>) agents, has been highlighted. The main advantage of POMs is that their properties (especially dimensions and charge) can be tailored to optimize the interaction with biological macromolecules (<xref ref-type="bibr" rid="B58">Arefian et al., 2017</xref>; <xref ref-type="bibr" rid="B28">Lentink et al., 2023</xref>). Moreover, they can be rationally synthesized on a multi-gram scale at a low cost.</p>
<p>POMs were generally proven to cross cell membranes, although with high toxicity and instability under physiological pH conditions (<xref ref-type="bibr" rid="B52">Wu and Liang, 2017</xref>). To overcome these drawbacks, different delivery systems were devised (<xref ref-type="bibr" rid="B8">Bijelic et al., 2019</xref>), while the POM architectures were successfully modified by introducing transition metals (such as Co, Ru or Mn) (<xref ref-type="bibr" rid="B50">Wang et al., 2014</xref>; <xref ref-type="bibr" rid="B19">Fabbian et al., 2022</xref>; <xref ref-type="bibr" rid="B12">Carvalho and Aureliano, 2023</xref>) or by grafting suitable organic pendants (<xref ref-type="bibr" rid="B11">Cameron et al., 2022</xref>). This last approach, consisting of the hybridization of inorganic POMs with organic or biological moieties, by exploiting weak interactions and/or covalent bonds, increases both stability and bioavailability (<xref ref-type="bibr" rid="B18">Dolbecq et al., 2010</xref>; <xref ref-type="bibr" rid="B14">Chang et al., 2022</xref>), and provides interesting opportunities for tracking (<xref ref-type="bibr" rid="B33">Modugno et al., 2018</xref>) and targeting (<xref ref-type="bibr" rid="B56">Zamolo et al., 2018</xref>; <xref ref-type="bibr" rid="B28">Lentink et al., 2023</xref>).</p>
<p>The Anderson-Evans polyoxometalates with the general formula [XM<sub>6</sub>O<sub>24</sub>]<sup>n-</sup> (<italic>n</italic> &#x3d; 2&#x2013;8) are constituted by six edge-sharing octahedra, MO<sub>6</sub> (M&#x3d;Mo or W), surrounding a central edge-sharing XO<sub>6</sub> octahedron containing the heteroatom (X&#x3d;Mn, Cr, I, etc.). The Mn-Anderson-Evans POM functionalized with TRIS (tris(hydroxymethyl)aminomethane), [(C<sub>4</sub>H<sub>9</sub>)<sub>4</sub>N]<sub>3</sub>[MnMo<sub>6</sub>O<sub>18</sub>{(OCH<sub>2</sub>)<sub>3</sub>CNH<sub>2</sub>}<sub>2</sub>] (<bold>POM-TRIS</bold>), and its derivatives have a proven cytotoxic effect on cancer cells (<xref ref-type="bibr" rid="B31">Mahvash et al., 2023</xref>). The functionalization of such POMs (<xref ref-type="bibr" rid="B9">Blazevic and Rompel, 2016</xref>) with biomolecules (<xref ref-type="bibr" rid="B53">Yang et al., 2013</xref>; <xref ref-type="bibr" rid="B23">Hosseini et al., 2021</xref>; <xref ref-type="bibr" rid="B38">Ramezani-Aliakbari et al., 2021</xref>) can thus be a convenient strategy to increase the bioactivity or to impart recognition ability. Among bio-conjugation opportunities, the interest in the use of peptides has recently increased (<xref ref-type="bibr" rid="B1">Albada and Metzler-Nolte, 2016</xref>), and there are already some examples dealing with the covalent associations of POMs with peptides (<xref ref-type="bibr" rid="B55">Yvon et al., 2014</xref>; <xref ref-type="bibr" rid="B29">Luo et al., 2023</xref>; <xref ref-type="bibr" rid="B44">Soria-Carrera et al., 2023</xref>). Within this <italic>scenario</italic>, the Anderson-Evans POM was decorated with Demobesin-1 (<bold>1</bold>, see <xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref ref-type="bibr" rid="B48">Ventura et al., 2018</xref>), a variant of bombesin peptide (QRLGNQWAVGHLM-NH<sub>2</sub>) isolated in amphibians, which is an antagonist of the gastrin-releasing peptide (GRP). The ability to target GRP-receptors (<xref ref-type="bibr" rid="B2">Aprikian et al., 1996</xref>; <xref ref-type="bibr" rid="B40">Rozengurt, 1998</xref>), overexpressed in different human cancers, including lung, stomach, prostate, ovarian and breast cancer (<xref ref-type="bibr" rid="B20">Gugger and Reubi, 1999</xref>; <xref ref-type="bibr" rid="B32">Markwalder and Reubi, 1999</xref>; <xref ref-type="bibr" rid="B42">Schally and Nagy, 1999</xref>; <xref ref-type="bibr" rid="B37">Pooja et al., 2019</xref>), makes bombesin derivatives suitable tools to drive cytotoxic drugs into tumor cells (<xref ref-type="bibr" rid="B34">Nock et al., 2003</xref>; <xref ref-type="bibr" rid="B13">Cescato et al., 2008</xref>). However, once conjugated to the POM core, peptide <bold>1</bold> did not impart any positive effect on the activity of the resulting bio-hybrid <bold>1-POM</bold>, probably due to an unfavorable interaction between peptide side-chains and POM surface, that hampered the recognition of target receptors (<xref ref-type="bibr" rid="B41">Rubini et al., 2010</xref>). To improve the bioavailability of <bold>1</bold>, a spacer composed of (i) an anionic region, containing four glutamic acids and a &#x3b2;-alanine residue (EEEE-&#x3b2;A) and (ii) a non-ionic Ttds tail, was conjugated to the N-terminal amino moiety of <bold>1</bold> (to produce peptide <bold>4</bold>, see <xref ref-type="sec" rid="s10">Supplementary Figure S1</xref>) (<xref ref-type="bibr" rid="B45">Tagliavini et al., 2021</xref>). The resulting POM (<bold>4-POM</bold>) showed better performance in terms of tumor cell recognition and is thus encouraging a further development of this approach.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Aminoacidic sequence of the peptides <bold>1-4</bold>, and structure of hybrids <bold>2-POM</bold> and <bold>3-POM</bold> (only one pendant is shown; tetrabutyl ammonium cations are also omitted).</p>
</caption>
<graphic xlink:href="fchbi-03-1377357-g001.tif"/>
</fig>
<p>In this work, the Mn-Anderson-Evans was functionalized with two <bold>1</bold> analogs containing one of the two portions of the previously described spacer. Peptide <bold>2</bold> contains only the Ttds group, while peptide <bold>3</bold> only the EEEE-&#x3b2;A anionic domain (<xref ref-type="fig" rid="F1">Figure 1</xref>). The corresponding POM constructs (<bold>2-POM</bold> and <bold>3-POM</bold>) were prepared (<xref ref-type="fig" rid="F1">Figure 1</xref> and <xref ref-type="sec" rid="s10">Supplementary Figure S1</xref>) and compared with spacer-free, and Ttds-EEEE-&#x3b2;A containing POMs (<bold>1-POM</bold> and <bold>4-POM</bold>, respectively), to investigate the contribution of different spacers. POM hybrids were characterized by various spectroscopic techniques, including ESI-MS, FT-IR, 2D-NMR, UV-Vis, CD and fluorimetry, DLS, TEM, and tested <italic>in vitro</italic> on cancer cells. Owing to its interesting properties, <bold>3-POM</bold> was also investigated by MD calculations to explain the observed behavior.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<sec id="s2-1">
<title>2.1 Reagents</title>
<p>Fmoc-amino acids, N-Fmoc-N-succinyl-4,7,10-trioxa-1,13-tridecanediamine (Fmoc-Ttds-OH), N,N-diisopropylethylamine (DIPEA), 2-(7-azabenzotriazol-1-yl)-N,N,N&#x2032;,N&#x2032;-tetramethyluronium hexafluorophosphate (HATU), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 1-hydroxybenzotriazole (HOBt), trifluoroacetic acid (TFA), piperidine, triisopropylsilane, were obtained from Iris Biotech. Tris(hydroxymethyl)aminomethane (TRIS), succinic anhydride, N,N&#x2032;-dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), DMF, diethyl ether, were purchased from Sigma-Aldrich and used without any further treatment.</p>
</sec>
<sec id="s2-2">
<title>2.2 Instruments</title>
<p>Nuclear Magnetic Resonance (NMR) Spectroscopy was performed on a Bruker DMX-400 instrument (Bruker Corporation, Billerica, MA, USA) operating at 399.92&#xa0;MHz for <sup>1</sup>H. Proton chemical shifts, in parts per million (ppm), are referred to the residual <sup>1</sup>H-DMSO solvent signal in DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub> (&#x3b4;&#x2009;&#x3d;&#x2009;2.49&#xa0;ppm). About 4&#xa0;mg of each sample were dissolved in 600&#xa0;&#x3bc;L DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub> for analysis. All NMR experiments have been carried out at temperature of 298&#xa0;K. One-dimensional (1D) <sup>1</sup>H-NMR spectra were acquired using typically 32 scans with 32K data size. For the two-dimensional (2D) <sup>1</sup>H NMR spectra, including COSY (Correlation Spectroscopy), TOCSY (Total Correlation Spectroscopy), and ROESY (Rotating Frame Overhauser Effect Spectroscopy), homonuclear pulse programs of the standard Bruker library were used (cosygpmfqf for COSY experiments, mlevetgp for TOCSY experiments, roesyetgp for ROESY experiments). Typically, 512 experiments of 50 scans each were performed: relaxation delay T2 equal to 1; size 4K; 5,597&#xa0;Hz spectral width in F2. Spectral processing was performed using the software TopSpin.</p>
<p>Infrared Spectra were collected by preparing KBr pellets, on a Nicolet 5700 FI-IR instrument (Thermo Fisher Scientific, Waltham, MA; USA).</p>
<p>Electrospray Ionization Mass Spectroscopy (ESI-MS) was performed on a LC/MSD Trap SL Agilent instrument (Agilent Technologies, Santa Clara, CA, USA). The samples were dissolved in CH<sub>3</sub>CN and analyzed in negative mode.</p>
<p>High-performance liquid chromatography (HPLC) analyses were run on a Shimadzu system equipped with a binary pump (LC-10AD), SCL-10A controller, Knauer detector and Gastorr 154 degasser. The semi-preparative HPLC was performed on a Shimadzu system equipped with a binary pump (LC-8A), a SCL-8A controller, SPD-6A detector and ERMA (ERC-3562) degasser (Shimadzu Corporation, Kyoto, Japan).</p>
<p>Circular dichroism and UV-vis spectra were acquired on a Jasco J-1500 CD spectrometer combined with a Jasco PTC-423S temperature controller (JASCO Corporation, Tokyo, Japan). For Circular Dichroism (CD) analysis, 1&#xa0;mg/mL stock solutions were prepared in TFE and diluted to 0.1&#xa0;mg/mL in the investigated TFE/water mixtures (%TFE&#x3d; 10, 20, 40, 60, 80, 100), which were prepared in 2&#xa0;mL flasks. Far-UV CD spectra were collected (at least 16 scans per sample) in the 190&#x2013;260&#xa0;nm range in 0.1&#xa0;cm pathlength quartz cuvettes (Hellma GmbH &#x26; Co., M&#xfc;llheim, Germany) at 25&#xb0;C at 50&#xa0;nm/min scanning speed, 1&#xa0;s response time, 1&#xa0;nm bandwidth, 200 mdeg sensitivity, 0.5&#xa0;nm datapitch. The secondary structure estimation (SSE) analysis of CD spectra was performed both using the Jasco Spectra manager application and the CDApps software developed at B23 beamline of the Diamond Light Source synchrotron (Didcot, UK) (<xref ref-type="bibr" rid="B24">Hussain et al., 2015</xref>), enabling signal deconvolution by means of the CONTINLL algorithm (encompassing &#x3b1;-helix, distorted &#x3b1; -helix, &#x3b2;-strand, distorted &#x3b2;-strand, turns and unordered reference structures).</p>
<p>Emission fluorescence experiments were collected on a Perkin Elmer LS50B spectrofluorimeter, equipped with FL-WinLab software (PerkinElmer, Inc., Waltham, MA, USA). Samples were measured in 10&#xa0;mm pathlength quartz cuvettes at 25&#xb0;C. Emission spectra were recorded in the range 300&#x2013;550&#xa0;nm, with excitation at &#x3bb;&#x3d;295&#xa0;nm, 3.5&#xa0;nm excitation and emission slits and 400&#xa0;nm/min scan speed. The spectra were the average of 4 scans.</p>
<p>Dynamic Light Scattering (DLS) was monitored by a Zetasizer Nano ZS instrument (Malvern Panalytical Ltd, UK), collecting 3 series of measurements from 0.2&#xa0;mM solutions in phosphate buffer (10&#xa0;mM, pH 7) with 3% DMSO.</p>
<p>Transmission Electron Microscopy (TEM) was carried out using a FEI Tecnai G2 instrument (Thermo Fisher Scientific, Waltham, MA, USA), drop casting aqueous solutions (with 3% DMSO) onto copper grids.</p>
</sec>
<sec id="s2-3">
<title>2.3 Cytotoxicity tests</title>
<p>Cytotoxicity/viability tests were performed as 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide (MTT) assays. For the experiments, HeLa cervical cancer (LGC Standards S.r.l., Sesto San Giovanni, Italy), cultured according to the manufacturer&#x2019;s instructions, were used. On day 1, 10,000 HeLa cervical cancer cells/well in a volume of 200&#xa0;&#xb5;L were plated in 96-wells plates, as previously reported (<xref ref-type="bibr" rid="B45">Tagliavini et al., 2021</xref>). The cells were exposed for 24, and 48&#xa0;h to different concentrations of <bold>POM-TRIS</bold>, <bold>2-POM</bold>, <bold>3-POM</bold> (5, 25, 50, 100, and 150&#xa0;&#x3bc;M). Stock solutions with 100&#xa0;mM POM in water, containing 5% DMSO, were prepared by prior solubilization of POMs in DMSO, followed by dilution in water. The results were expressed as the mean&#x2009;&#xb1;&#x2009;SD percentage of living cells normalized to the control.</p>
</sec>
<sec id="s2-4">
<title>2.4 Molecular Dynamics (MD) investigations</title>
<p>The coordinates of the POM moiety, that was kept frozen during the simulations, were taken from the published crystal structure (<xref ref-type="bibr" rid="B39">Rosnes et al., 2012</xref>). For the peptide moieties, a fully extended starting structure was used. The peptide chains and the POM peptide complexes were build using standard molecular manipulation tools. For the peptides, the GROMOS 54a7 force field was used (<xref ref-type="bibr" rid="B43">Schmid et al., 2011</xref>). The parameters for non-standard residues were obtained by analogy with similar already parameterized chemical groups. As the POM structure is kept fixed during the MD simulations, only non-bonded parameters were derived, i.e., partial atomic charges and Lennard-Jones parameters. The partial atomic charges were evaluated from quantum chemical calculations on the isolated POM moiety bound on both sides to an amino group (see <xref ref-type="fig" rid="F1">Figure 1</xref>). RESP charges (<xref ref-type="bibr" rid="B3">Bayly et al., 1993</xref>) were calculated at the density functional theory (DFT) level (<xref ref-type="bibr" rid="B36">Parr and Yang, 1995</xref>) with the B3LYP functional (<xref ref-type="bibr" rid="B4">Becke, 1993</xref>). The atomic basis sets were as follows: (i) for the Mn and Mo atoms, the LANL2DZ effective core potential for the inner electrons and a double Gaussian basis set of (5S,5P,5D)/[3S,3P,2D] quality for the valence electrons were used (<xref ref-type="bibr" rid="B21">Hay and Wadt, 1985</xref>); (ii) for the hydrogen, carbon, oxygen and nitrogen atoms, a standard 6-31&#x2b;G(d) Gaussian basis set was used (<xref ref-type="bibr" rid="B27">Krishnan et al., 2008</xref>). Quantum chemical calculations were performed with the Gaussian09 package (M. <xref ref-type="bibr" rid="B25">Jea Frisch et al., 2009</xref>). The Lennard-Jones parameters for the POM were taken from the universal force field (UFF).</p>
<p>The POM-peptide hybrids were solvated in a dodecahedral box, large enough to contain the solute (with the peptides in the extended conformation) and at least 1.0&#xa0;nm of solvent on all sides. Water was modeled by the simple point charge (SPC) model (<xref ref-type="bibr" rid="B5">Berendsen et al., 1987</xref>). The LINCS algorithm (<xref ref-type="bibr" rid="B22">Hess et al., 1997</xref>) was used to constrain bond lengths and a time step of 2 fs for numerical integration of the equations of motion was used. The particle mesh Ewald method (<xref ref-type="bibr" rid="B17">Darden et al., 1993</xref>) was used for the calculation of the long-range interactions and a cut-off of 1.1&#xa0;nm was used. After a solute optimization and a subsequent solvent relaxation, each system was gradually heated from 50 to 300&#xa0;K using short MD simulations. Then, a short (100 ps) equilibration simulation was performed for the two systems in the NPT ensemble with the velocity rescaling temperature coupling (<xref ref-type="bibr" rid="B10">Bussi et al., 2007</xref>) to keep the temperature constant at 300&#xa0;K and the Berendsen pressure coupling (<xref ref-type="bibr" rid="B6">Berendsen et al., 1984</xref>) to keep the pressure constant at 1&#xa0;bar. Three productive independent 100 ns-long MD simulations for each system were then carried out in the NVT ensemble at 300&#xa0;K. For both compound <bold>1</bold>-<bold>POM</bold> and compound <bold>3</bold>-<bold>POM</bold>, the same starting structure was used for each of the three simulations, varying the initial velocities randomly generated conforming to a Maxwell velocity distribution at 300&#xa0;K. The MD simulations were performed with the GROMACS (<xref ref-type="bibr" rid="B47">Van Der Spoel et al., 2005</xref>) software package. The secondary structure of the peptides was analyzed with the DSSP tool (<xref ref-type="bibr" rid="B26">Kabsch and Sander, 1983</xref>) of the GROMACS package.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>3 Results and discussion</title>
<sec id="s3-1">
<title>3.1 Peptide and POM-peptide synthesis</title>
<p>Peptides <bold>1-4</bold> were prepared by solid phase synthesis adopting the Fmoc/HBTU strategy, according to the previously described procedure (<xref ref-type="bibr" rid="B41">Rubini et al., 2010</xref>; <xref ref-type="bibr" rid="B48">Ventura et al., 2018</xref>; <xref ref-type="bibr" rid="B45">Tagliavini et al., 2021</xref>). The N-ethylamide group was introduced <italic>ab initio</italic> using an ethyl-indole AM Resin. The peptides were purified by HPLC and characterized by ESI-MS, FT-IR and 2D-NMR (see <xref ref-type="sec" rid="s10">Supplementary Figures S2&#x2013;S11</xref>, showing the characterization of peptides <bold>2</bold> and <bold>3</bold>).</p>
<p>[(C<sub>4</sub>H<sub>9</sub>)<sub>4</sub>N]<sub>3</sub>[MnMo<sub>6</sub>O<sub>18</sub>((OCH<sub>2</sub>)<sub>3</sub>CNH<sub>2</sub>)<sub>2</sub>] <bold>POM-TRIS</bold> was synthesized by addition of TRIS and manganese (III) acetate to [(C<sub>4</sub>H<sub>9</sub>)<sub>4</sub>N]<sub>4</sub>[Mo<sub>8</sub>O<sub>26</sub>] in refluxing acetonitrile for 24&#xa0;h (58% yield). The <bold>POM-TRIS</bold> was then reacted with succinic anhydride in molar ratio 1:20&#xa0;at 50&#xb0;C in DMF for 24&#xa0;h to obtain [(C<sub>4</sub>H<sub>9</sub>)<sub>4</sub>N]<sub>3</sub>[MnMo<sub>6</sub>O<sub>18</sub>{(OCH<sub>2</sub>)<sub>3</sub>CNHCO(CH<sub>2</sub>)<sub>2</sub>COOH}<sub>2</sub>] (<bold>POM-succ</bold>, 74% yield), which was activated by reaction with NHS/DCC in DMF at room temperature for 1&#xa0;day, to obtain [(C<sub>4</sub>H<sub>9</sub>)<sub>4</sub>N]<sub>3</sub>[MnMo<sub>6</sub>O<sub>18</sub>{(OCH<sub>2</sub>)<sub>3</sub>CNHCO(CH<sub>2</sub>)<sub>2</sub>CO(C<sub>4</sub>H<sub>4</sub>NO<sub>3</sub>)}<sub>2</sub>] (<bold>POM-NHS</bold>, 68% yield) (<xref ref-type="sec" rid="s10">Supplementary Figure S1</xref>) (<xref ref-type="bibr" rid="B55">Yvon et al., 2014</xref>).</p>
<p>The syntheses of the <bold>1</bold>-<bold>4-POM</bold> hybrids were performed in air, at room temperature for 24&#xa0;h, under continuous stirring (<xref ref-type="sec" rid="s10">Supplementary Figure S1</xref>) (<xref ref-type="bibr" rid="B48">Ventura et al., 2018</xref>; <xref ref-type="bibr" rid="B45">Tagliavini et al., 2021</xref>). To this aim, <bold>POM-NHS</bold> and 2 equivs. of peptides (<bold>1-4</bold>) were dissolved in DMF, then DIPEA was added. The obtained solutions were placed in a closed vessel under diethyl ether vapors, for 24&#xa0;h, to allow the precipitation of the products, which were finally washed with diethyl ether and dried under air, to achieve pale orange solids (yields &#x3e;85%).</p>
<p>All POM-peptides conjugates were characterized by ESI-MS, FT-IR, 2D-NMR, CD, UV-vis (see <xref ref-type="sec" rid="s10">Supplementary Figures S12&#x2013;S27</xref>, showing the characterization of <bold>2-POM</bold> and <bold>3-POM</bold>).</p>
<p>FT-IR and ESI-MS are quick and useful tools to assess the successful conjugation. FTIR show the replacement of the C&#x3d;O signals of NHS group, around 1740&#xa0;cm<sup>&#x2212;1</sup>, by a band at 1,650&#x2013;1,685&#xa0;cm<sup>&#x2212;1</sup> due to the amide C&#x3d;O bond and by a peak ascribed to N-H bending at 1,535&#x2013;1,543&#xa0;cm<sup>&#x2212;1</sup>. The integrity of the inorganic POM scaffold was confirmed by the retention of the bands at 942, 920&#x2013;921, 900&#x2013;902 and 663&#x2013;670&#xa0;cm<sup>&#x2212;1</sup> (<xref ref-type="sec" rid="s10">Supplementary Figures S12, S20</xref>). ESI-MS (-) spectra show the bis-functionalized POMs, detected as di- or tri-anionic species (<xref ref-type="sec" rid="s10">Supplementary Figures S13, S21</xref>).</p>
</sec>
<sec id="s3-2">
<title>3.2 NMR investigation</title>
<p>The resonance assignment of amino acid residues in peptides <bold>2</bold> and <bold>3</bold> and their corresponding <bold>POM</bold> derivatives were obtained by collecting COSY, TOCSY and ROESY spectra for all samples (<xref ref-type="sec" rid="s10">Supplementary Tables S1&#x2013;S4</xref>). Due to the limited solubility of POM hybrids in water, the analysis was performed in DMSO<italic>-d</italic>
<sub>
<italic>6</italic>
</sub>. The latter is also useful for the study of peptides that interact with membrane receptors, having a dielectric constant (&#x3b5; 47.5) very close to that of the membrane interface (&#x3b5; 40).</p>
<p>Information on the secondary structure of peptides was obtained from the secondary chemical shift (&#x394;&#x3b4;) values of the H<sup>&#x3b1;</sup>, calculated by subtracting representative random coil values from the observed H<sup>&#x3b1;</sup> shift. In DMSO<italic>-d</italic>
<sub>
<italic>6</italic>
</sub>, a minimum of four values of &#x394;&#x3b4; less than &#x2212;0.16&#xa0;ppm or greater than 0.22&#xa0;ppm are indicative of the presence of &#x3b1;-helix or &#x3b2;-sheet secondary structures, respectively (<xref ref-type="bibr" rid="B46">Tremblay et al., 2010</xref>). According to these threshold values, it is possible to assess how the C-terminal regions of all peptides have a propensity to adopt a helical structure (see Val, Gly, His, Leu residues in <xref ref-type="fig" rid="F2">Figure 2A</xref>), with the most negative &#x394;&#x3b4; values observed for peptide <bold>2</bold>. Once conjugated on the POM, the peptides generally show even more negative &#x394;&#x3b4; values. The signals of peptide <bold>1</bold> show the biggest changes (see &#x394;&#x3b4; values for Gln and Trp residues before and after grafting, <xref ref-type="fig" rid="F2">Figure 2</xref>), with a tendency to form the helical structure also at the N-terminus. <bold>2-POM</bold>, instead, displays its most negative &#x394;&#x3b4; value at the His residue, towards the C-terminus.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Secondary H&#x3b1; chemical shift (&#x394;&#x3b4;) values of DB-1 derivatives <bold>(A)</bold> or of the corresponding POM-peptide hybrids <bold>(B)</bold>. The dotted line indicates the threshold value for the presence of a helical secondary structure.</p>
</caption>
<graphic xlink:href="fchbi-03-1377357-g002.tif"/>
</fig>
<p>To evaluate the spacers&#x2019; contribution on the interactions between POM and different peptides, the NH and H&#x3b1; secondary chemical shift values, determined by subtracting the NH and H<sup>&#x3b1;</sup> resonance of each peptide to the resonance of corresponding POM construct were also compared (<xref ref-type="fig" rid="F3">Figure 3</xref>). The presence of POM cluster had an evident impact in the resonance of the closer N-terminal peptide region in <bold>1-POM</bold> and <bold>2-POM</bold>, indicating that the introduction of the negatively charged Glu<sub>4</sub>-&#x3b2;Ala sequence (in <bold>3-POM</bold> and <bold>4-POM</bold>) seems useful to attenuate the interaction between the peptide and the inorganic cluster.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Influence of spacer on NH <bold>(A)</bold> and H&#x3b1; <bold>(B)</bold> resonances of DB-1 in POM-peptide constructs. Secondary chemical shift values were determined by subtracting the NH or H&#x3b1; chemical shift values of DB-1 analogues (peptide <bold>1-4</bold>) to the resonance of corresponding POM constructs (<bold>POM 1-4</bold>). Values greater than &#x7c;0.15&#x7c; ppm (dotted lines) indicate a significant effect on resonances.</p>
</caption>
<graphic xlink:href="fchbi-03-1377357-g003.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>3.3 Circular dichroism spectroscopy</title>
<p>The far-UV (185&#x2013;260&#xa0;nm) CD spectrum of peptide is largely determined by the electronic transitions of the amide chromophores and provides useful information on its secondary structure. To overcome the high absorbance of DMSO in the far-UV region, that hinders its use as solvent in CD spectroscopy, 2,2,2-trifluoroethanol (TFE) was used as the solvent. TFE, in addition to being an excellent solvent for both peptide and the POM, is widely used to mimic the cell membrane environment (<xref ref-type="bibr" rid="B30">Ma et al., 2015</xref>). The influence of TFE on the secondary structure of peptides <bold>2</bold> and <bold>3</bold> was evaluated by recording CD spectra at increasing TFE percentages, so to monitor the behavior of the compounds in an environment with decreasing polarity (CD spectra in <xref ref-type="fig" rid="F4">Figure 4</xref>; <xref ref-type="sec" rid="s10">Supplementary Figures S28, S29, S32, S33</xref>), without the need of screening other solvents, where they display low solubility.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Far-UV CD spectra of <bold>2</bold> and <bold>2-POM (A)</bold>, and of and <bold>3</bold> and <bold>3-POM (B)</bold>, at 10 and 80% (v/v) TFE percentages (indicated). The spectra were recorded by a Jasco J-1500 spectropolarimeter using a 0.1&#xa0;cm pathlength Suprasil quartz cuvette, 1&#xa0;nm bandwidth, 50&#xa0;nm/min scan speed, 1&#xa0;nm data pitch, 1&#xa0;s&#xa0;d.i.t.</p>
</caption>
<graphic xlink:href="fchbi-03-1377357-g004.tif"/>
</fig>
<p>At a low percentage of TFE (10% v/v), the CD spectra of peptides <bold>2</bold> and <bold>3</bold> show a negative band at 197&#x2013;200&#xa0;nm (n &#x2192; &#x3c0;&#x2a; electronic transition) and a positive band at &#x3bb;&#x3c;190&#xa0;nm (&#x3c0; &#x2192; &#x3c0;&#x2a;), ascribed to an unordered conformation. In 80% TFE, the CD spectra of peptides <bold>2</bold> and <bold>3</bold> are characterized by a positive band at 192&#xa0;nm and a negative band around 206&#xa0;nm, generated by the presence of more ordered structures, involving an increased contribution of the &#x3b1;-helical structure.</p>
<p>Parallel experiments on POM-peptide constructs showed that, at low percentages of TFE (10% v/v, <xref ref-type="fig" rid="F4">Figure 4</xref>), the introduction of the POM moiety influences the position of the dichroic bands, whose negative minima display a shift to &#x3bb; &#x3d; 202&#x2013;204&#xa0;nm. As far as the bands intensity is concerned, the double value of ellipticity is due to the presence of two peptide chains in the hybrids. Moreover, <bold>3-POM</bold> shows a stronger signal than <bold>2-POM</bold>, (with &#x398; &#x3d; 2.7&#xd7;10<sup>5</sup> deg cm<sup>2</sup>&#xa0;dmol<sup>-1</sup> at &#x3bb; &#x3d; 204 vs. 1.6&#xd7;10<sup>5</sup> deg cm<sup>2</sup>&#xa0;dmol<sup>&#x2212;1</sup> at &#x3bb; &#x3d; 202&#xa0;nm, respectively, see <xref ref-type="sec" rid="s10">Supplementary Figures S15, S23</xref>), likely due also to the presence of additional aminoacids in <bold>3-POM</bold>. In such condition, &#x3b2;-strand and random coil are the main conformations (37%&#x2013;38% and 32%&#x2013;35%, respectively). At higher TFE percentage (&#x2265;80% v/v), the bands further increase their intensity, especially the positive one at 191&#xa0;nm (&#x398; &#x3d; 5.4 &#xd7; 10<sup>5</sup> and 7.5 &#xd7; 10<sup>5</sup> deg cm<sup>2</sup>&#xa0;dmol<sup>-1</sup> for <bold>2-POM</bold> and <bold>3-POM</bold>, respectively, see <xref ref-type="sec" rid="s10">Supplementary Figures S29, S33</xref>), highlighting a strong tendency of the peptide to adopt to &#x3b1;-helix (up to 59%&#x2013;68%) when exposed to the less hydrophilic medium and conjugated with the POM. The behavior observed in non-aqueous system is in agreement with the NMR analysis in DMSO<italic>-d</italic>
<sub>
<italic>6</italic>
</sub>, and it is the result of a double effect: on one hand, TFE acts as secondary structure stabilizer, primarily inducing &#x3b1;-helical conformation (<xref ref-type="bibr" rid="B49">Vincenzi et al., 2019</xref>), on the other hand, the conjugation with POM may also assist the evolution to &#x3b1;-helix, as previously reported by (<xref ref-type="bibr" rid="B55">Yvon et al., 2014</xref>) for a different POM-peptide conjugate dissolved in CH<sub>3</sub>CN. Considering the estimated ratio between &#x3b1;-helix and &#x3b2;-strands in different TFE/H<sub>2</sub>O mixtures, hybrid POMs appear much more sensitive than free peptides to solvent change, being <bold>2-POM</bold> the one showing the highest amount of &#x3b1;-helix (<xref ref-type="sec" rid="s10">Supplementary Figures S30, S31, S34&#x2013;S36</xref>). Nevertheless, the differences in the intensity of the bands level off when the compounds are situated in TFE &#x2265;80% v/v.</p>
<p>For a sake of comparison, <bold>1-POM</bold> and <bold>4-POM</bold> showed the highest and the lowest impact on DB-1 folding, favoring, respectively, &#x3b1;-helix and &#x3b2;-strand conformations (<xref ref-type="bibr" rid="B48">Ventura et al., 2018</xref>; <xref ref-type="bibr" rid="B45">Tagliavini et al., 2021</xref>). In summary, the two spacers, Ttds and EEEE&#x3b2;A, have a relatively similar effect in terms of secondary structure evolution in H<sub>2</sub>O/TFE, and their behavior is intermediate with respect to the spacer-free and double-spacer POMs.</p>
<p>Interestingly, when POM and peptide are not conjugated (see <xref ref-type="sec" rid="s10">Supplementary Figure S37</xref>, reporting the example for peptide <bold>3</bold> in the presence of 0.5 equiv. of <bold>POM-succ</bold>) no significant difference was observed in the CD spectra of peptide with or without POM at both the examined TFE percentages (10 and 40% v/v). This suggests that non-covalent interactions between POM and peptides are of intramolecular type and that the increase of dichroic signal observed for the hybrids can be due to an induction of chirality to the POM core in a less polar solvent, where intramolecular hydrogen bonds are promoted.</p>
</sec>
<sec id="s3-4">
<title>3.4 Fluorescence spectroscopy</title>
<p>Additional information on the interaction between peptides and POM was obtained analyzing the fluorescence emission of the Trp residue, being its emission dependent on the chemical surroundings. Comparing the emission wavelengths and the intensity of the Trp fluorescence in equimolar solutions of peptides alone or graphed to POM we did not observe a relevant shift of the maximum wavelength emission of Trp residue, suggesting that the POM did not alter the chemical surrounding of the Trp side-chain. Nevertheless, the emission intensity is always less intense in graphted peptides than in the corresponding free peptide, highlighting the occurrence of an energy transfer from the peptide to the POM (<xref ref-type="bibr" rid="B57">Zhang et al., 2007</xref>). Fluorescence quenching experiments were then performed adding cesium ions, to provide information on the exposure of the Trp side-chain. In <xref ref-type="fig" rid="F5">Figure 5</xref> the observed fluorescence (F), at &#x3bb;&#x3d; 295&#xa0;nm, is reported, as F/F0, with respect to the initial one (F<sub>0</sub>). Instead of observing a further quenching of the fluorescence, however, Cs<sup>&#x2b;</sup> induced an increase in fluorescence emission, suggesting that the added ions disrupt the interaction between POM moiety and peptide, consequently making less efficient the energy transfer between the two domains (<xref ref-type="bibr" rid="B45">Tagliavini et al., 2021</xref>). The increase in fluorescent emission is more evident in <bold>1-POM</bold> construct and decreases with increasing spacer length. <bold>2-POM</bold> shows intermediate behavior, being also sensitive to the addition of Cs<sup>&#x2b;</sup> in terms of fluorescence recovery, while <bold>3-POM</bold> and <bold>2-POM</bold> appeared almost insensitive to Cs<sup>&#x2b;</sup>. The behavior observed upon addition of KI has a trend in agreement with previous data, with fluorescence increasing for <bold>1-POM</bold>&#x3e;<bold>2-POM</bold> and fluorescence quenching being more effective for <bold>4-POM</bold> than for <bold>3-POM</bold>, that can only be quenched at higher KI concentrations (<xref ref-type="sec" rid="s10">Supplementary Figure S38</xref>). In the same conditions, peptides <bold>1-4</bold> showed the expected quenching of the signal, with efficiency in the order <bold>1</bold>&#x3e;<bold>2</bold>&#x3e;<bold>3</bold>&#x3d;<bold>4</bold>, in agreement with the repulsion between negative charges of I<sup>&#x2212;</sup> and Glu residues in <bold>3</bold> and <bold>4</bold>.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Fluorescence emission of POM-peptide hybrids (indicated) at increasing amounts of cesium ions (CsCl). Fluorescence is referred to as the ratio between the fluorescence at a given quencher concentration (F) and the fluorescence in its absence (F<sub>0</sub>).</p>
</caption>
<graphic xlink:href="fchbi-03-1377357-g005.tif"/>
</fig>
<p>These fluorescence experiments highlight a greater impact of the spacers in terms of peptide-POM interactions rather than POM-induced secondary structure evolution, demonstrating the need to attenuate them to increase peptide availability.</p>
</sec>
<sec id="s3-5">
<title>3.5 Transmission Electron Microscopy</title>
<p>The formation of aggregates may also have a strong impact on the accessibility of peptide chains. TEM was employed to achieve information about size and shape of the nanoparticles (<xref ref-type="fig" rid="F6">Figure 6</xref>). In water with 3% DMSO, <bold>1-POM</bold> forms particles with diameter up to 50&#xa0;nm diameter (<xref ref-type="bibr" rid="B45">Tagliavini et al., 2021</xref>), <bold>2-POM</bold> assembles into fibers of 200&#x2013;300&#xa0;nm in length, whereas <bold>3-POM</bold>, in agreement with DLS data (showing particles with hydrodynamic diameter of 30&#x2013;50&#xa0;nm, see <xref ref-type="sec" rid="s10">Supplementary Figure S39</xref>), forms amorphous particles with diameter smaller than 50&#xa0;nm. Compound <bold>4-POM</bold> shows entangled fibers in the 300&#x2013;500&#xa0;nm diameter range. To understand the role of POM, with respect to that of the peptides, in driving the morphology of the aggregates, we have also monitored the behavior of <bold>POM-TRIS</bold>, <bold>POM-succ</bold> and of a mixture of both. <bold>POM-TRIS</bold> (casted form acetonitrile solution) displays a tendency to align, forming fibers between 500&#xa0;nm and 3&#xa0;&#x3bc;m in length, as shown in <xref ref-type="sec" rid="s10">Supplementary Figure S40</xref>, suggesting that the 1D morphology is likely dictated by POMs. On the contrary, <bold>POM-succ</bold> forms polyhedral crystals-like structures (<xref ref-type="sec" rid="s10">Supplementary Figure S41</xref>). Moreover, fibers longer than 500&#xa0;nm, differently from the ones formed by <bold>POM-TRIS</bold>, can be obtained by mixing equimolar amounts of <bold>POM-TRIS</bold> and <bold>POM-succ</bold> in acetonitrile, as represented in <xref ref-type="sec" rid="s10">Supplementary Figure S42</xref>. Complementary interactions (amino groups/POM surface and amino groups/carboxylic groups) are thus also useful to establish directional interactions. Highly negatively charged POMs, as <bold>POM-succ</bold> and <bold>3-POM</bold>, instead, only form nanoparticles.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>TEM measurements, 10<sup>&#x2212;4</sup>&#xa0;M solutions of a <bold>(A) 1-POM</bold>, scale bar &#x3d;100&#xa0;nm <bold>(B) 2-POM</bold> in 3% DMSO/water, scale bar &#x3d;200&#xa0;nm; <bold>(C) 3-POM</bold> in H<sub>2</sub>O, scale bar 100&#xa0;nm; <bold>(D) 4-POM</bold> in 3% DMSO/water, scale bar 500&#xa0;nm.</p>
</caption>
<graphic xlink:href="fchbi-03-1377357-g006.tif"/>
</fig>
<p>Noteworthy, in DMF as solvent, <bold>2-POM</bold> showed a gelator effect, likely mediated by the polar Ttds chains (<xref ref-type="sec" rid="s10">Supplementary Figure S43</xref>), as previously observed also for <bold>4-POM</bold> (<xref ref-type="bibr" rid="B45">Tagliavini et al., 2021</xref>). These results underly how hybrid POMs may represent versatile building blocks, capable of exploiting both the polyanionic surface and the organic pendants to control the interactions.</p>
</sec>
<sec id="s3-6">
<title>3.6 MD simulations</title>
<p>From the data collected, it is evident that the spacer based on the tetra glutamic acid has a bigger impact than Ttds on improving the accessibility of the peptide chains. Indeed, <bold>POM-3</bold> showed better behavior in terms of:<list list-type="simple">
<list-item>
<p>&#x2022; retention of POM-free peptide&#x2019;s secondary structure in DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>,</p>
</list-item>
<list-item>
<p>&#x2022; higher accessibility of the peptide chain with respect to quenching by ions,</p>
</list-item>
<list-item>
<p>&#x2022; lower tendency to aggregate.</p>
</list-item>
</list>
</p>
<p>MD simulations were thus performed to elucidate the structural features of <bold>POM-3</bold>, comparing the outcomes with those of <bold>1-POM</bold>, in order to focus only on the effects of the addition of the anionic spacer. The structure and dynamics were studied by means of three independent 100 ns-long MD simulations for each compound, starting from an extended conformation for the peptide moiety. Such a starting conformation allows the secondary structure of both peptides to evolve in an unbiased way, highlighting possible differences. The analysis of the secondary structure sampled in the MD simulations is reported in <xref ref-type="fig" rid="F7">Figure 7</xref>, where the time evolution of the fraction of &#x3b2;-structure, helical structure and unstructured peptide is shown for both compounds. It must be noted that a relevant amount of unstructured peptide is present in the MD simulations (&#x2248;50% on average), while in the experimental CD data a lower percentage of unstructured peptides was observed (32&#x2013;35%). This can be ascribed to the relatively short simulation time (100 ns for each MD) that does not allow the peptides to assume a stable folded conformation. However, relevant structural differences between the two compounds can be already observed: in both compounds the peptides assume a &#x3b2;-structure, but in compound <bold>1-POM</bold> a non-negligible fraction of helical structure is also present. The formation of helical structure is observed in two of the three simulations of <bold>1-POM</bold>: in the third simulation, a particularly high unstructured fraction is present, and no helical structure is observed. <bold>3-POM</bold> shows a bigger amount of &#x3b2;-structures. Similarly to the previous case, in the first simulation of compound <bold>3-POM</bold> a more relevant percentage of helical structure is present with respect to the other two simulations of the same compound. The statistical sampling of different secondary structures is not surprising in MD simulations starting from an extended conformation. However, the difference in the average secondary structure content between the two compounds appears to be meaningful.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Time evolution of the relative abundance of &#x3b2;-structure (red), helical structure (blue) and unstructured peptide (gray) along the three independent MD simulations of compound <bold>1-POM</bold> (upper panels) and compound <bold>3-POM</bold> (lower panels). In the right panels, the same fractions, averaged along the three simulations, are reported for both compounds. To calculate such average values, the first 10 ns of each MD simulation have been neglected.</p>
</caption>
<graphic xlink:href="fchbi-03-1377357-g007.tif"/>
</fig>
<p>During the MD simulations, the peptide bent on the POM. In some cases, the POM-peptide interaction was stabilized by the formation of hydrogen bonds between the peptide and the oxygen atoms of the POM. An example of such bending is reported in <xref ref-type="fig" rid="F8">Figure 8</xref>. The bending of the peptide on the POM moiety, monitored along the six MD simulations by plotting the distance between the peptide terminal residue and the POM center of mass, does not seem to be related to the structural differences. In fact, a similar distribution for the terminal residue to POM distance is obtained for both compounds (<xref ref-type="sec" rid="s10">Supplementary Figure S44</xref>). This fact is important to explain the presence of interactions despite the presence of electrostatic repulsions and deserves attention, in terms or length of the peptide and functionality at the terminal end, for further structural optimization.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Time evolution of the distance between the terminal residue of the two peptides and the center of mass of the POM moiety in one of the MD simulations of compound <bold>3-POM</bold>. The black and red lines refer to the two pendants. Some representative snapshots of the POM-peptides conformation are also shown.</p>
</caption>
<graphic xlink:href="fchbi-03-1377357-g008.tif"/>
</fig>
<p>The interactions between the two peptide chains, belonging to the same POM, were finally investigated for the two compounds, revealing that, in compound <bold>1-POM</bold>, more interactions between the two peptide chains are present compared to compound <bold>3-POM</bold>. This can be observed from <xref ref-type="fig" rid="F9">Figure 9</xref>, where the time fraction of interchain contacts along the simulations of the two compounds is reported. Such a fraction is defined as follows. Being R<sub>i</sub> and R<sub>j</sub> the i<sup>th</sup> and j<sup>th</sup> residues of the two peptide chains, respectively, a contact between R<sub>i</sub> and R<sub>j</sub> is present at each MD frame in which the minimum distance <italic>d</italic> between R<sub>i</sub> and R<sub>j</sub> is below 0.5&#xa0;nm. <xref ref-type="fig" rid="F10">Figure 10</xref> clearly shows that the two peptide chains are more frequently interacting during the MD simulations of compound <bold>1-POM</bold>. The increased interchain interactions between the two peptides disfavor the formation of intrachain interactions. As a matter of fact, it can be observed in <xref ref-type="sec" rid="s10">Supplementary Figure S45</xref> that the number of intrachain hydrogen bonds (HB) in <bold>3-POM</bold> is higher with respect to that in <bold>1-POM</bold>. Nonetheless, the same Figure also shows that the number of interchain HBs is similar for <bold>1-POM</bold> and <bold>3-POM</bold>, suggesting that hydrogen bonding is not the main interchain interaction. Inspection of the trajectories reveals that interchain contacts in <bold>1-POM</bold> are stabilized by aromatic interactions among His, Phe and Trp residues, that are often arranged in a sort of aromatic cleft (<xref ref-type="sec" rid="s10">Supplementary Figure S46</xref>).</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Fraction of interchain contacts in compounds <bold>1-POM</bold> (left) and <bold>3-POM</bold> (right). The color code represents the fraction of MD frames at which an Ri Rj contact is present.</p>
</caption>
<graphic xlink:href="fchbi-03-1377357-g009.tif"/>
</fig>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>Cytotoxicity performances of <bold>3-POM</bold> on HeLa cells at increasing concentration. Results are presented after 24 and 48&#xa0;h.</p>
</caption>
<graphic xlink:href="fchbi-03-1377357-g010.tif"/>
</fig>
<p>The amount of such transient interactions is likely related to the different conformations observed; in particular, they can make the chains less available for longer range interactions required for &#x3b2;-structures as well as for targeting purposes.</p>
</sec>
<sec id="s3-7">
<title>3.7 Cytotoxicity tests</title>
<p>The toxicity assessments were performed on HeLa cervical cancer cells, which show a moderate overexpression of the bombesin receptor. While the peptides <bold>2</bold> and <bold>3</bold>, as well as <bold>2-POM</bold> exhibit only a minor anticancer activity, (IC<sub>50</sub>&#x3e;200&#xa0;&#x3bc;M), <bold>3-POM</bold> led to 58% residual viability at 150&#xa0;&#x3bc;M after 48&#xa0;h (IC<sub>50</sub> 180&#xa0;&#x3bc;M at 48&#xa0;h, <xref ref-type="fig" rid="F10">Figure 10</xref>). With respect to <bold>POM-TRIS</bold> (IC<sub>50</sub>&#x3d;134&#xa0;&#x3bc;M, with 46% residual viability at 150&#xa0;&#x3bc;M after 48&#xa0;h) and <bold>4-POM</bold> (IC<sub>50</sub>&#x3d;95&#xa0;&#x3bc;M, with 33% residual viability at 150&#xa0;&#x3bc;M after 48&#xa0;h), the <bold>3-POM</bold> is, thus, less active. However, with respect to <bold>1-POM</bold>, which was also less active than <bold>POM-TRIS</bold> (<xref ref-type="bibr" rid="B48">Ventura et al., 2018</xref>), it shows a better activity. Moreover, the stronger effect observed at 25&#xa0;&#x3bc;M of <bold>3-POM</bold>, with respect to <bold>POM-TRIS</bold>, speaks in favor of a higher selectivity, at least, in the low concentration range (<xref ref-type="table" rid="T1">Table 1</xref>). These outcomes are consistent with the data herein collected, confirming, on one hand, the significant impact of tetra glutamic acid domain, on the other hand, the need of combining the two spacers to achieve a stronger biological activity.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>IC<sub>50</sub> values ad residual viability, observed for HeLa cells treated with POMs, after 48&#xa0;h incubation.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Compound</th>
<th align="left">POM-TRIS</th>
<th align="left">3-POM</th>
<th align="left">4-POM</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">IC<sub>50</sub> (&#x3bc;M)</td>
<td align="left">134</td>
<td align="left">180</td>
<td align="left">95</td>
</tr>
<tr>
<td align="left">Residual viability</td>
<td rowspan="2" align="left">95%</td>
<td rowspan="2" align="left">82%</td>
<td rowspan="2" align="left">72%</td>
</tr>
<tr>
<td align="left">at 25&#xa0;&#x3bc;M</td>
</tr>
<tr>
<td align="left">Residual viability</td>
<td rowspan="2" align="left">46%</td>
<td rowspan="2" align="left">58%</td>
<td rowspan="2" align="left">33%</td>
</tr>
<tr>
<td align="left">at 150&#xa0;&#x3bc;M</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>4 Conclusion</title>
<p>This study delves into the asymmetric environment of novel Mn-Anderson POM-hybrids with potential anticancer activity. Specifically, distinct spacers, EEEE&#x3b2;A and Ttds, were introduced between the POM core and the pendant peptides, with the aim to maintain the peptide chains easily accessible even after grafting, so to facilitate the targeting of cancer cells. Peptide folding is, indeed, a common phenomenon in the presence of salts or other chaotropic agents, including POMs, and could lead to a decrease of biological activity (<xref ref-type="bibr" rid="B44">Soria-Carrera et al., 2023</xref>).</p>
<p>The incorporation of spacers could mitigate the influence of the POM cluster. According to 2D NMR, among the two spacers, EEEE&#x3b2;A and Ttds, the first proved to be more useful in minimizing molecular interactions. The negatively charged spacer, indeed, was confirmed to have a positive effect, as <bold>3-POM</bold> and <bold>4-POM</bold> showed lower CH<sup>&#x3b1;</sup> shifts compared to the free peptide. In contrast, compounds <bold>1-POM</bold> and <bold>2-POM</bold> displayed more differences in the secondary structure compared to bare Demobesin-1, favouring the formation of &#x3b1;-helix in DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>. However, the impact of the two spacers on secondary structure seemed not relevant in TFA/H<sub>2</sub>O solutions: CD spectroscopy did not highlight a meaningful difference between <bold>2-POM</bold> and <bold>3-POM</bold>, which both displayed intermediate behavior with respect to <bold>1-POM</bold> and <bold>4-POM</bold>. Quenching of fluorescence, instead, underscored the positive effect conferred by the charged spacer, with compounds <bold>1-POM</bold> and <bold>2-POM</bold> exhibiting no dynamic quenching upon the addition of both KI and CsCl, while <bold>3-POM</bold> and <bold>4-POM</bold> showed better responsivity of the side chain Trp.</p>
<p>MD calculation showed that <bold>3-POM</bold> secondary structure is mostly composed by &#x3b2;-sheet and random coil conformations, with minor interchain interactions. Despite the high accessibility of the chains, however, they still tend to fold on the POM structure, exploiting the terminal residues for the interactions. For this reason, the biological activity of <bold>3-POM</bold> towards HeLa cells appears still low, and justifies the need for a longer spacer, provided by the addition of Ttds, as for <bold>4-POM</bold>. This observation may be crucial to overcome the general problem of undesired POM-triggered peptide folding, and will be useful to drive the design of a next generation of POM-based drugs, with possibility to control targeting and delivery, while enabling mechanistic studies for the still unclear mechanism of action of anticancer POMs. Further studied will evaluate the nature of POM scaffold.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s10">Supplementary Material</xref>, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s6">
<title>Author contributions</title>
<p>HY: Data curation, Writing&#x2013;original draft, Formal Analysis, Investigation, Software. CH: Methodology, Validation, Writing&#x2013;original draft, Formal Analysis, Investigation, Software. MF: Formal Analysis, Investigation, Software, Writing&#x2013;original draft. NB: Formal Analysis, Investigation, Software, Writing&#x2013;original draft. VT: Formal Analysis, Investigation, Writing&#x2013;original draft. XZ: Formal Analysis, Investigation, Writing&#x2013;original draft. ES: Formal Analysis, Investigation, Writing&#x2013;original draft. AC: Writing&#x2013;original draft, Data curation. SS: Writing&#x2013;original draft, Investigation, Formal Analysis, Methodology. AA: Formal Analysis, Writing&#x2013;original draft, Data curation, Methodology. LP: Writing&#x2013;original draft, Formal Analysis, Methodology. LZ: Writing&#x2013;original draft, Methodology, Software, Validation. SC: Writing&#x2013;original draft, Software, Validation, Methodology. PR: Conceptualization, Data curation, Methodology, Resources, Supervision, Validation, Writing&#x2013;original draft, Writing&#x2013;review and editing. MC: Methodology, Writing&#x2013;original draft, Conceptualization, Data curation, Project administration, Resources, Supervision, Validation, Writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s7">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Department of Chemical Sciences of the University of Padova (grant number P-DiSC&#x23;11NExuS_BIRD2019-UNIPD) and by MUR (project PRIN2022CAS9ZT).</p>
</sec>
<ack>
<p>HY thanks the China Scholarship Council for funding her PhD in Molecular Science at Padova University.</p>
</ack>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s10">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fchbi.2024.1377357/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fchbi.2024.1377357/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.PDF" id="SM1" mimetype="application/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albada</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Metzler-Nolte</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Organometallic-peptide bioconjugates: synthetic strategies and medicinal applications</article-title>. <source>Chem. Rev.</source> <volume>116</volume> (<issue>19</issue>), <fpage>11797</fpage>&#x2013;<lpage>11839</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.6b00166</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aprikian</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chevalier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bazinet</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Viallet</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells</article-title>. <source>J. Mol. Endocrinol.</source> <volume>16</volume> (<issue>3</issue>), <fpage>297</fpage>&#x2013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1677/jme.0.0160297</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arefian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mirzaei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eshtiagh-Hosseini</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Frontera</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>A survey of the different roles of polyoxometalates in their interaction with amino acids, peptides and proteins</article-title>. <source>Dalton Trans.</source> <volume>46</volume>, <fpage>6812</fpage>&#x2013;<lpage>6829</lpage>. <pub-id pub-id-type="doi">10.1039/C7DT00894E</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bayly</surname>
<given-names>C. I.</given-names>
</name>
<name>
<surname>Cieplak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cornell</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kollman</surname>
<given-names>P. A.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model</article-title>. <source>J. Phys. Chem.</source> <volume>97</volume> (<issue>40</issue>), <fpage>10269</fpage>&#x2013;<lpage>10280</lpage>. <pub-id pub-id-type="doi">10.1021/j100142a004</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becke</surname>
<given-names>A. D.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Density-functional thermochemistry. III. The role of exact exchange</article-title>. <source>J. Chem. Phys.</source> <volume>98</volume> (<issue>7</issue>), <fpage>5648</fpage>&#x2013;<lpage>5652</lpage>. <pub-id pub-id-type="doi">10.1063/1.464913</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berendsen</surname>
<given-names>H. J. C.</given-names>
</name>
<name>
<surname>Grigera</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Straatsma</surname>
<given-names>T. P.</given-names>
</name>
</person-group> (<year>1987</year>). <article-title>The missing term in effective pair potentials</article-title>. <source>J. Phys. Chem.</source> <volume>91</volume> (<issue>24</issue>), <fpage>6269</fpage>&#x2013;<lpage>6271</lpage>. <pub-id pub-id-type="doi">10.1021/j100308a038</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berendsen</surname>
<given-names>H. J. C.</given-names>
</name>
<name>
<surname>Postma</surname>
<given-names>J. P. M.</given-names>
</name>
<name>
<surname>van Gunsteren</surname>
<given-names>W. F.</given-names>
</name>
<name>
<surname>DiNola</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Haak</surname>
<given-names>J. R.</given-names>
</name>
</person-group> (<year>1984</year>). <article-title>Molecular dynamics with coupling to an external bath</article-title>. <source>J. Chem. Phys.</source> <volume>81</volume> (<issue>8</issue>), <fpage>3684</fpage>&#x2013;<lpage>3690</lpage>. <pub-id pub-id-type="doi">10.1063/1.448118</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bijelic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aureliano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rompel</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The antibacterial activity of polyoxometalates: structures, antibiotic effects and future perspectives</article-title>. <source>Chem. Commun.</source> <volume>54</volume> (<issue>10</issue>), <fpage>1153</fpage>&#x2013;<lpage>1169</lpage>. <pub-id pub-id-type="doi">10.1039/C7CC07549A</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bijelic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aureliano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rompel</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Polyoxometalates as potential next-generation metallodrugs in the combat against cancer</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>58</volume> (<issue>10</issue>), <fpage>2980</fpage>&#x2013;<lpage>2999</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201803868</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blazevic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rompel</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The Anderson&#x2013;Evans polyoxometalate: from inorganic building blocks via hybrid organic&#x2013;inorganic structures to tomorrows &#x201c;Bio-POM&#x201d;</article-title>. <source>Coord. Chem. Rev.</source> <volume>307</volume>, <fpage>42</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2015.07.001</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bussi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Donadio</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Parrinello</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Canonical sampling through velocity rescaling</article-title>. <source>J. Chem. Phys.</source> <volume>126</volume> (<issue>1</issue>), <fpage>014101</fpage>. <pub-id pub-id-type="doi">10.1063/1.2408420</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cameron</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Guillemot</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Galambos</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Hampson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mall Haidaraly</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Supramolecular assemblies of organo-functionalised hybrid polyoxometalates: from functional building blocks to hierarchical nanomaterials</article-title>. <source>Chem. Soc. Rev.</source> <volume>51</volume> (<issue>1</issue>), <fpage>293</fpage>&#x2013;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1039/D1CS00832C</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carvalho</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Aureliano</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Polyoxometalates impact as anticancer agents</article-title>. <source>Int. J. Mol. Sci.</source> <volume>24</volume> (<issue>5</issue>), <fpage>5043</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24055043</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cescato</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Maina</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nock</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nikolopoulou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Charalambidis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Piccand</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Bombesin receptor antagonists may Be preferable to agonists for tumor targeting</article-title>. <source>J. Nucl. Med.</source> <volume>49</volume> (<issue>2</issue>), <fpage>318</fpage>&#x2013;<lpage>326</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.107.045054</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Polyoxometalate-based nanocomposites for antitumor and antibacterial applications</article-title>. <source>Nanoscale Adv.</source> <volume>4</volume> (<issue>18</issue>), <fpage>3689</fpage>&#x2013;<lpage>3706</lpage>. <pub-id pub-id-type="doi">10.1039/D2NA00391K</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>&#x10c;olovi&#x107;</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Lackovi&#x107;</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lalatovi&#x107;</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mougharbel</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Kortz</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Krsti&#x107;</surname>
<given-names>D. Z.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Polyoxometalates in biomedicine: update and overview</article-title>. <source>Curr. Med. Chem.</source> <volume>27</volume> (<issue>3</issue>), <fpage>362</fpage>&#x2013;<lpage>379</lpage>. <pub-id pub-id-type="doi">10.2174/0929867326666190827153532</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fujinami</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sumitomo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ogiwara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Suhara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Konno</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Application of antiviral polyoxometalates to living environments&#x2014;antiviral moist hand towels and stationery items</article-title>. <source>Appl. Sci.</source> <volume>10</volume> (<issue>22</issue>), <fpage>8246</fpage>. <pub-id pub-id-type="doi">10.3390/app10228246</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Darden</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>York</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Particle mesh Ewald: an N&#x22c5;log(N) method for Ewald sums in large systems</article-title>. <source>J. Chem. Phys.</source> <volume>98</volume> (<issue>12</issue>), <fpage>10089</fpage>&#x2013;<lpage>10092</lpage>. <pub-id pub-id-type="doi">10.1063/1.464397</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolbecq</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dumas</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Mialane</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Hybrid Organic&#x2212;Inorganic polyoxometalate compounds: from structural diversity to applications</article-title>. <source>Chem. Rev.</source> <volume>110</volume> (<issue>10</issue>), <fpage>6009</fpage>&#x2013;<lpage>6048</lpage>. <pub-id pub-id-type="doi">10.1021/cr1000578</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabbian</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Giachin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bellanda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Borgo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ruzzene</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Spuri</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Mechanism of CK2 inhibition by a ruthenium-based polyoxometalate</article-title>. <source>Front. Mol. Biosci.</source> <volume>9</volume>, <fpage>906390</fpage>. <pub-id pub-id-type="doi">10.3389/fmolb.2022.906390</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gugger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Reubi</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast</article-title>. <source>Am. J. Pathology</source> <volume>155</volume> (<issue>6</issue>), <fpage>2067</fpage>&#x2013;<lpage>2076</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)65525-3</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hay</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Wadt</surname>
<given-names>W. R.</given-names>
</name>
</person-group> (<year>1985</year>). <article-title>
<italic>Ab initio</italic> effective core potentials for molecular calculations. Potentials for K to Au including the outermost core orbitals</article-title>. <source>J. Chem. Phys.</source> <volume>82</volume> (<issue>1</issue>), <fpage>299</fpage>&#x2013;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1063/1.448975</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hess</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bekker</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Berendsen</surname>
<given-names>H. J. C.</given-names>
</name>
<name>
<surname>Fraaije</surname>
<given-names>JGEM</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>LINCS: a linear constraint solver for molecular simulations</article-title>. <source>J. Comput. Chem.</source> <volume>18</volume> (<issue>12</issue>), <fpage>1463</fpage>&#x2013;<lpage>1472</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1096-987X(199709)18:12&#x3c;1463::AID-JCC4&#x3e;3.0.CO;2-H</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hosseini</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Haghjooy Javanmard</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dana</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rafiee</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rostami</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Novel tocopherol succinate-polyoxomolybdate bioconjugate as potential anti-cancer agent</article-title>. <source>J. Inorg. Organomet. Polym. Mater.</source> <volume>31</volume> (<issue>7</issue>), <fpage>3183</fpage>&#x2013;<lpage>3195</lpage>. <pub-id pub-id-type="doi">10.1007/s10904-021-01998-z</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hussain</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Benning</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Javorfi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rudd</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Pulford</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>CDApps: integrated software for experimental planning and data processing at beamline B23, Diamond Light Source</article-title>. <source>J. Synchrotron Radiat.</source> <volume>22</volume> (<issue>2</issue>), <fpage>465</fpage>&#x2013;<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1107/S1600577514028161</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Jea Frisch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trucks</surname>
<given-names>G. W.</given-names>
</name>
<name>
<surname>Schlegel</surname>
<given-names>H. B.</given-names>
</name>
<name>
<surname>Scuseria</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Robb</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Cheeseman</surname>
<given-names>J. R.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <source>Gaussian 09, revision a. 1</source>. <publisher-loc>Wallingford, CT</publisher-loc>: <publisher-name>Gaussian Inc.</publisher-name>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kabsch</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>1983</year>). <article-title>Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features</article-title>. <source>Biopolymers</source> <volume>22</volume> (<issue>12</issue>), <fpage>2577</fpage>&#x2013;<lpage>2637</lpage>. <pub-id pub-id-type="doi">10.1002/bip.360221211</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Binkley</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Seeger</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pople</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>1980</year>). <article-title>Self&#x2010;consistent molecular orbital methods. XX. A basis set for correlated wave functions</article-title>. <source>J. Chem. Phys.</source> <volume>72</volume> (<issue>1</issue>), <fpage>650</fpage>&#x2013;<lpage>654</lpage>. <pub-id pub-id-type="doi">10.1063/1.438955</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lentink</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Salazar Marcano</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Moussawi</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Vandebroek</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Van Meervelt</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Parac-Vogt</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Fine-tuning non-covalent interactions between hybrid metal-oxo clusters and proteins</article-title>. <source>Faraday Discuss.</source> <volume>244</volume> (<issue>0</issue>), <fpage>21</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1039/D2FD00161F</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yvon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hutin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gerislioglu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wesdemiotis</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Self&#x2010;assembly of polyoxometalate&#x2013;peptide hybrids in solution: elucidating the contributions of multiple possible driving forces</article-title>. <source>Eur. J. Inorg. Chem.</source> <volume>2019</volume>, <fpage>380</fpage>&#x2013;<lpage>386</lpage>. <pub-id pub-id-type="doi">10.1002/ejic.201800158</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Characterization of cell selectivity, physiological stability and endotoxin neutralization capabilities of &#x3b1;-helix-based peptide amphiphiles</article-title>. <source>Biomaterials</source> <volume>52</volume>, <fpage>517</fpage>&#x2013;<lpage>530</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2015.02.063</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahvash</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zavareh</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Taymouri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mirian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ramezani-Aliakbari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dousti</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Anderson-type manganese polyoxomolybdate hybrid nanocomposite for boosting drug delivery against breast cancer</article-title>. <source>J. Drug Deliv. Sci. Technol.</source> <volume>87</volume>, <fpage>104778</fpage>. <pub-id pub-id-type="doi">10.1016/j.jddst.2023.104778</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Markwalder</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Reubi</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation</article-title>. <source>Cancer Res.</source> <volume>59</volume> (<issue>5</issue>), <fpage>1152</fpage>&#x2013;<lpage>1159</lpage>.</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Modugno</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fabbretti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dalle Vedove</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Da Ros</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Maccato</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hosseini</surname>
<given-names>H. S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Tracking fluorescent polyoxometalates within cells</article-title>. <source>Eur. J. Inorg. Chem.</source> <volume>2018</volume> (<issue>46</issue>), <fpage>4955</fpage>&#x2013;<lpage>4961</lpage>. <pub-id pub-id-type="doi">10.1002/ejic.201800802</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nock</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nikolopoulou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chiotellis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Loudos</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Maintas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Reubi</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>[99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging</article-title>. <source>Eur. J. Nucl. Med. Mol. Imaging</source> <volume>30</volume> (<issue>2</issue>), <fpage>247</fpage>&#x2013;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1007/s00259-002-1040-x</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Omwoma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gore</surname>
<given-names>C. T.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y. F.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Environmentally benign polyoxometalate materials</article-title>. <source>Coord. Chem. Rev.</source> <volume>286</volume>, <fpage>17</fpage>&#x2013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2014.11.013</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parr</surname>
<given-names>R. G.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Density-functional theory of the electronic structure of molecules</article-title>. <source>Annu. Rev. Phys. Chem.</source> <volume>46</volume> (<issue>1</issue>), <fpage>701</fpage>&#x2013;<lpage>728</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.pc.46.100195.003413</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pooja</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gunukula</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Kulhari</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Bombesin receptors as potential targets for anticancer drug delivery and imaging</article-title>. <source>Int. J. Biochem. Cell Biol.</source> <volume>114</volume>, <fpage>105567</fpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2019.105567</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramezani-Aliakbari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soltanabadi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sadeghi-aliabadi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Varshosaz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yadollahi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hassanzadeh</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Eudesmic acid-polyoxomolybdate organo-conjugate as novel anticancer agent</article-title>. <source>J. Mol. Struct.</source> <volume>1240</volume>, <fpage>130612</fpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2021.130612</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosnes</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Yvon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Cronin</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Mapping the synthesis of low nuclearity polyoxometalates from octamolybdates to Mn-Anderson clusters</article-title>. <source>Dalton Trans.</source> <volume>41</volume> (<issue>33</issue>), <fpage>10071</fpage>&#x2013;<lpage>10079</lpage>. <pub-id pub-id-type="doi">10.1039/C2DT31008B</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rozengurt</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Signal transduction pathways in the mitogenic response to G protein&#x2013;coupled neuropeptide receptor agonists</article-title>. <source>J. Cell. Physiology</source> <volume>177</volume> (<issue>4</issue>), <fpage>507</fpage>&#x2013;<lpage>517</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1097-4652(199812)177:4&#x3c;507::AID-JCP2&#x3e;3.0.CO;2-K</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ruzza</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Spaller</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Siligardi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hussain</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Udugamasooriya</surname>
<given-names>D. G.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Recognition of lysine-rich peptide ligands by murine cortactin SH3 domain: CD, ITC, and NMR studies</article-title>. <source>Biopolymers</source> <volume>94</volume> (<issue>3</issue>), <fpage>298</fpage>&#x2013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1002/bip.21350</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schally</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Nagy</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors</article-title>. <source>Eur. J. Endocrinol.</source> <volume>141</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1530/eje.0.1410001</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmid</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Eichenberger</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Choutko</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Riniker</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Winger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mark</surname>
<given-names>A. E.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Definition and testing of the GROMOS force-field versions 54A7 and 54B7</article-title>. <source>Eur. Biophysics J.</source> <volume>40</volume> (<issue>7</issue>), <fpage>843</fpage>&#x2013;<lpage>856</lpage>. <pub-id pub-id-type="doi">10.1007/s00249-011-0700-9</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soria-Carrera</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Atri&#xe1;n-Blasco</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mart&#xed;n-Rap&#xfa;n</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>S. G.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Polyoxometalate&#x2013;peptide hybrid materials: from structure&#x2013;property relationships to applications</article-title>. <source>Chem. Sci.</source> <volume>14</volume> (<issue>1</issue>), <fpage>10</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1039/D2SC05105B</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tagliavini</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Honisch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Serrat&#xec;</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Azzariti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bonchio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ruzza</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Enhancing the biological activity of polyoxometalate&#x2013;peptide nano-fibrils by spacer design</article-title>. <source>RSC Adv.</source> <volume>11</volume> (<issue>9</issue>), <fpage>4952</fpage>&#x2013;<lpage>4957</lpage>. <pub-id pub-id-type="doi">10.1039/D0RA10218K</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tremblay</surname>
<given-names>M.-L.</given-names>
</name>
<name>
<surname>Banks</surname>
<given-names>A. W.</given-names>
</name>
<name>
<surname>Rainey</surname>
<given-names>J. K.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>The predictive accuracy of secondary chemical shifts is more affected by protein secondary structure than solvent environment</article-title>. <source>J. Biomol. NMR</source> <volume>46</volume> (<issue>4</issue>), <fpage>257</fpage>&#x2013;<lpage>270</lpage>. <pub-id pub-id-type="doi">10.1007/s10858-010-9400-5</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Der Spoel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lindahl</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hess</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Groenhof</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mark</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Berendsen</surname>
<given-names>H. J. C.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>GROMACS: fast, flexible, and free</article-title>. <source>J. Comput. Chem.</source> <volume>26</volume> (<issue>16</issue>), <fpage>1701</fpage>&#x2013;<lpage>1718</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.20291</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ventura</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Calderan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Honisch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Krol</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Serrat&#xec;</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bonchio</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Synthesis and biological activity of an Anderson polyoxometalate bis-functionalized with a Bombesin-analog peptide</article-title>. <source>Peptide Sci.</source> <volume>110</volume> (<issue>5</issue>), <fpage>e24047</fpage>. <pub-id pub-id-type="doi">10.1002/pep2.24047</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vincenzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mercurio</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Leone</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>About TFE: old and new findings</article-title>. <source>Curr. protein &#x26; peptide Sci.</source> <volume>20</volume> (<issue>5</issue>), <fpage>425</fpage>&#x2013;<lpage>451</lpage>. <pub-id pub-id-type="doi">10.2174/1389203720666190214152439</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B. B.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Z. H.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>L. L.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>The inhibitory effects of a new cobalt-based polyoxometalate on the growth of human cancer cells</article-title>. <source>Dalton Trans.</source> <volume>43</volume> (<issue>16</issue>), <fpage>6070</fpage>&#x2013;<lpage>6078</lpage>. <pub-id pub-id-type="doi">10.1039/C3DT53030B</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S.-S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.-Y.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Recent advances in polyoxometalate-catalyzed reactions</article-title>. <source>Chem. Rev.</source> <volume>115</volume> (<issue>11</issue>), <fpage>4893</fpage>&#x2013;<lpage>4962</lpage>. <pub-id pub-id-type="doi">10.1021/cr500390v</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2017</year>). &#x201c;<article-title>Polyoxometalates and their complexes toward biological application</article-title>,&#x201d; in <source>Supramolecular Chemistry of biomimetic systems</source>. Editor <person-group person-group-type="editor">
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
</person-group> (<publisher-loc>Singapore</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>311</fpage>&#x2013;<lpage>354</lpage>. <pub-id pub-id-type="doi">10.1007/978-981-10-6059-5_13</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>H.-K.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Y. X.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Polyoxometalate&#x2013;biomolecule conjugates: a new approach to create hybrid drugs for cancer therapeutics</article-title>. <source>Bioorg. Med. Chem. Lett.</source> <volume>23</volume> (<issue>5</issue>), <fpage>1462</fpage>&#x2013;<lpage>1466</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2012.12.081</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Multiscale assembly of polyoxometalates: from clusters to materials</article-title>. <source>ChemPhysMater</source> <volume>2</volume> (<issue>1</issue>), <fpage>20</fpage>&#x2013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.chphma.2022.03.006</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yvon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Surman</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Hutin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alex</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>B. O.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Polyoxometalate clusters integrated into peptide chains and as inorganic amino acids: solution- and solid-phase approaches</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>53</volume> (<issue>13</issue>), <fpage>3336</fpage>&#x2013;<lpage>3341</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201311135</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zamolo</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Modugno</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lubian</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cazzolaro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mancin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giotta</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Selective targeting of proteins by hybrid polyoxometalates: interaction between a bis-biotinylated hybrid conjugate and avidin</article-title>. <source>Front. Chem.</source> <volume>6</volume>, <fpage>278</fpage>. <pub-id pub-id-type="doi">10.3389/fchem.2018.00278</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Keita</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Brochon</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nadjo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Craescu</surname>
<given-names>C. T.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Molecular interaction and energy transfer between human serum albumin and polyoxometalates</article-title>. <source>J. Phys. Chem. B</source> <volume>111</volume> (<issue>7</issue>), <fpage>1809</fpage>&#x2013;<lpage>1814</lpage>. <pub-id pub-id-type="doi">10.1021/jp063758z</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>